Comment
. 2018 Mar; 28(5):501-502.
doi: 10.1038/s41422-018-0031-9.

Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy

Jonathan Pol 1 Guido Kroemer 2 
Affiliations
  • PMID: 29593340
  •     12 References
  •     9 citations

No abstract available

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.
Padmanee Sharma, James P Allison.
Cell, 2015 Apr 11; 161(2). PMID: 25860605    Free PMC article.
Highly Cited. Review.
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Mark J Selby, John J Engelhardt, +4 authors, Alan J Korman.
Cancer Immunol Res, 2014 Apr 30; 1(1). PMID: 24777248
Highly Cited.
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.
Emanuela Romano, Monika Kusio-Kobialka, +7 authors, Daniel E Speiser.
Proc Natl Acad Sci U S A, 2015 Apr 29; 112(19). PMID: 25918390    Free PMC article.
Highly Cited.
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
Udupi A Ramagopal, Weifeng Liu, +10 authors, Steven C Almo.
Proc Natl Acad Sci U S A, 2017 May 10; 114(21). PMID: 28484017    Free PMC article.
Coinhibitory Pathways in Immunotherapy for Cancer.
Susanne H Baumeister, Gordon J Freeman, Glenn Dranoff, Arlene H Sharpe.
Annu Rev Immunol, 2016 Mar 02; 34. PMID: 26927206
Highly Cited. Review.
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
Xuexiang Du, Fei Tang, +14 authors, Yang Liu.
Cell Res, 2018 Feb 24; 28(4). PMID: 29472691    Free PMC article.
Highly Cited.
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Yannick Bulliard, Rose Jolicoeur, +6 authors, Jennifer L Brogdon.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897982    Free PMC article.
Highly Cited.
Ipilimumab and its toxicities: a multidisciplinary approach.
Leslie A Fecher, Sanjiv S Agarwala, F Stephen Hodi, Jeffrey S Weber.
Oncologist, 2013 Jun 19; 18(6). PMID: 23774827    Free PMC article.
Highly Cited. Review.
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice.
Xuexiang Du, Mingyue Liu, +8 authors, Pan Zheng.
Cell Res, 2018 Feb 22; 28(4). PMID: 29463898    Free PMC article.
Highly Cited.
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer.
James D Mellor, Michael P Brown, +2 authors, Alexander Dobrovic.
J Hematol Oncol, 2013 Jan 05; 6. PMID: 23286345    Free PMC article.
Highly Cited. Review.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.
Aurélien Marabelle, Holbrook Kohrt, +13 authors, Ronald Levy.
J Clin Invest, 2013 Jun 04; 123(6). PMID: 23728179    Free PMC article.
Highly Cited.
Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors.
Lara Gibellini, Sara De Biasi, +5 authors, Andrea Cossarizza.
Front Immunol, 2020 Apr 09; 11. PMID: 32265933    Free PMC article.
Review.
Immunotherapies and Combination Strategies for Immuno-Oncology.
Cody Barbari, Tyler Fontaine, +4 authors, Rahul R Deshmukh.
Int J Mol Sci, 2020 Jul 19; 21(14). PMID: 32679922    Free PMC article.
Review.
Mitosis in Cancer Cell Increases Immune Resistance via High Expression of HLA-G and PD-L1.
Matti Ullah, Warda Aoudjeghout, +2 authors, Massoud Mirshahi.
Cancers (Basel), 2020 Sep 24; 12(9). PMID: 32961872    Free PMC article.
Development of bispecific antibodies in China: overview and prospects.
Jing Zhang, Jizu Yi, Pengfei Zhou.
Antib Ther, 2021 May 01; 3(2). PMID: 33928227    Free PMC article.
Review.
Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies.
Bo-Cheng Huang, Yun-Chi Lu, +9 authors, Tian-Lu Cheng.
Chem Sci, 2021 Aug 06; 12(28). PMID: 34349949    Free PMC article.
The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives.
Aymara Sancho-Araiz, Victor Mangas-Sanjuan, Iñaki F Trocóniz.
Pharmaceutics, 2021 Aug 11; 13(7). PMID: 34371708    Free PMC article.
Review.
Trial watch: intratumoral immunotherapy.
Juliette Humeau, Julie Le Naour, +2 authors, Jonathan G Pol.
Oncoimmunology, 2021 Oct 23; 10(1). PMID: 34676147    Free PMC article.
Review.
Comprehensive Analysis of Innate Immunophenotyping Based on Immune Score Predicting Immune Alterations and Prognosis in Breast Cancer Patients.
Weiguang Liu, Lingling Xia, Zhengmiao Xia, Liming Chen.
Genes (Basel), 2022 Jan 22; 13(1). PMID: 35052427    Free PMC article.
A Hot Topic: Cancer Immunotherapy and Natural Killer Cells.
Tatiana Michel, Markus Ollert, Jacques Zimmer.
Int J Mol Sci, 2022 Jan 22; 23(2). PMID: 35054985    Free PMC article.
Review.